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ABSTRACT: The unique characteristics of the tumor
vasculature oﬀer the possibility to selectively target tumor
growth and vascularization using tubulin-destabilizing agents.
Evidence accumulated with combretastatin A-4 (CA-4) and its
prodrug CA-4P support the therapeutic value of compounds
sharing this mechanism of action. However, the chemical
instability and poor solubility of CA-4 demand alternative
compounds that are able to surmount these limitations. This
Perspective illustrates the diﬀerent classes of compounds that
behave similar to CA-4, analyzes their binding mode to αβ-
tubulin according to recently available structural complexes, and
includes described approaches to improve their delivery. In
addition, dissecting the mechanism of action of CA-4 and
analogues allows a closer insight into the advantages and
drawbacks associated with these tubulin-destabilizing agents that behave as vascular disrupting agents (VDAs).
1. TUMOR VASCULARIZATION
The requirement of vascularization for tumor growth and
metastasis has become one of the greatest areas of research in
recent years. It is widely accepted that a solid tumor cannot
grow further than approximately 2 mm3 without blood vessels
that provide oxygen and nutrients. Two main approaches have
been followed to target tumor vascularization: inhibition of
angiogenesis, that is, the formation of new blood vessels, or
targeting the already existing vasculature.1 Both approaches are
directed against endothelial cells, a cell type that is genetically
more stable and less prone to mutations compared to tumor
cells.2−4
Angiogenesis has been extensively investigated promoting
fundamental work on how this process occurs under
physiological and pathological conditions.5 There are currently
a number of approved drugs, both monoclonal antibodies and
small molecules, that are able to aﬀect this process.6 However,
from an anticancer perspective, antiangiogenic agents have not
accomplished their expectations. Clinical data indicate that
treatment with these agents is accompanied by lack of eﬃcacy,
resistance development, and toxicity.7 Still, antiangiogenic
agents have proven useful in combination therapies, and
applications outside cancer treatment continue to be explored.7
The second approach targeting the tumor vasculature relies
on the so-called vascular-disrupting agents, commonly
designated as VDAs.1 These agents target already existing
vessels in the tumor environment, thereby provoking a rapid
collapse of the tumor vasculature leading to necrosis at the
tumor core. Although it is not always easy to dissect between an
antiangiogenic and a VDA eﬀect, antiangiogenic agents are
considered to be cytostatic against endothelial cells and are
particularly active at early stage (small) tumors. These
compounds should ideally be administered for long periods,
so almost chronically. On the other hand, VDAs are cytotoxic
and exert an almost immediate eﬀect on the existing tumor
vessels leading to a rapid vascular collapse and subsequent
tumor cell death. Therefore, they are particularly eﬃcient
against large tumors and should be administered acutely.8
2. VASCULAR DISRUPTING AGENTS (VDAS)
2.1. Characteristics of the Tumor Vasculature. Vascular
endothelial cells are planar cells that cover the internal/luminal
surface of blood vessels, thus ensuring laminar blood ﬂow and
providing a nonthrombogenic surface. Endothelial cells are
highly heterogeneous and display diﬀerent morphologies and
functions depending on their location (e.g., liver versus lung,
macro- versus microvasculature). Moreover, signiﬁcant diﬀer-
ences exist between physiological vessels and vessels in the
tumor microenvironment.9 The normal vasculature is a well-
organized network that is strictly controlled by a balance
between proangiogenic and antiangiogenic factors and is
arranged in a hierarchy of well-diﬀerentiated arteries, arterioles,
capillaries, venules, and veins. In contrast, the overexpression of
proangiogenic factors in the tumor environment results in an
unevenly distributed and chaotic vasculature with irregular
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branches and the formation of arteriovenous shunts. Moreover,
tumor blood vessels are structurally abnormal and often lack
pericytes and a proper basement membrane, which makes these
vessels more fragile and immature (Figure 1).8 These
morphological abnormalities have a signiﬁcant impact on vessel
function, i.e., blood vessel permeability is increased in the
tumor, leading to extravasation of macromolecules and
increased interstitial pressure. Vascular resistance is equally
increased in tumor vessels, and blood ﬂow is reduced. Thus,
any alteration of blood vessel perfusion that would not be
relevant for a normal vessel may be catastrophic for the
intratumoral vasculature,2 leading to ischemia and tumor cell
death (Figure 1). Agents that may lead to such vascular
destruction were designated as VDAs.1 It should be noted that
imaging techniques provide evidence that the vascular damage
after VDA treatment is conﬁned to the tumor vessel network.8
It is also relevant to mention that cells at the outer rim of the
tumor are not aﬀected by the VDAs, probably due to
nutritional support from the nearby blood vessels which are
less responsive to VDAs.10
2.2. Classiﬁcation of VDAs. Early reviews on VDAs a
decade ago proposed a classiﬁcation of these agents in two
main groups:11 ligand-directed VDAs and small molecules
(Figure 2a). The ligand-directed VDAs make use of antibodies,
peptides, or growth factors to target toxins or procoagulants to
the tumor endothelium.12 The second class of VDAs contains
small molecules and has been further classiﬁed into derivatives
of 8-ﬂavon acetic acid (1, FAA, Figure 2a), designated as
ﬂavonoids in previous reviews,12 and tubulin-depolymerizing
agents. According to IUPAC recommendations, the ﬂavonoid
designation, currently under evaluation, is too wide and
includes among others, ﬂavones, isoﬂavones, neoﬂavones,
chalcones, dehydrochalcones, aurones, etc. As we will later
describe, compounds belonging to these structural families (i.e.,
chalcones) are tubulin-depolymerizing agents, so the desig-
nation of ﬂavone derivatives for this ﬁrst group should be more
accurate than ﬂavonoids, and we propose such designation.
FAA and its best studied derivative 5,6-dimethylxanthenone-
4-acetic acid (2, DMXAA, ASA404, Figure 2a)12 induce the
activation of nuclear factor κB (NF-κB) which increases the
production of various cytokines, including tumor necrosis
factor-α (TNF-α). As a consequence endothelial cells enter
apoptosis, leading to hemorrhagic necrosis of the tumor.
Compound 2 was discontinued after phase III clinical trials
against advanced NSCLC.13,14 More details about the biological
activity of FAA and DMXAA can be found in a very recent
review.15
The second group of small molecules that behave as VDAs
has been designated as tubulin-depolymerizing VDAs,8 and
they will be the subject of this Perspective. This group
comprises a very large and structurally diverse group of
compounds that bind at the colchicine site in tubulin.
2.3. VDAs Acting at Tubulin. Microtubules are dynamic
structures that, together with actin microﬁlaments and
intermediate ﬁlaments, constitute the cellular cytoskeleton.
Besides their well-known role in cell division, their functions
involve maintenance of cell shape and morphology, cellular
motility, and traﬃcking of organelles and vesicles.16 Micro-
tubules are formed by the polymerization of heterodimers of α
and β tubulin. These heterodimers assemble head to tail into
linear protoﬁlaments, which further polymerize in a polar
manner to form the microtubules that have a plus end where β-
tubulin is exposed and a minus end where the α-subunit is
present (Figure 2b). Binding and hydrolysis of GTP at the
microtubule ends is directly involved in microtubule dynam-
ics.16
Colchicine (3) (Figure 2a) is a natural alkaloid present in
diﬀerent species particularly in Colchicum autumnale. In 1968,
this alkaloid was used for the identiﬁcation of tubulin, a protein
unknown until then.17 Colchicine was characterized as a potent
cytotoxic agent that binds tubulin at the αβ-tubulin interface18
and causes microtubule depolymerization,19 probably by
inhibiting assembly of the protoﬁlaments. However, due to a
very narrow therapeutic window, colchicine has been discarded
as an antitumor drug, although at lower doses it is used for the
treatment of gout, familiar Mediterranean fever, osteoarthritis,
pericarditis, and atherosclerosis.20
Figure 1. Schematic representation of the eﬀects of VDA treatment on tumor vascularization. (a) In the normal vasculature, blood vessels are
organized hierarchically and the basement membrane and pericytes provide structure and stability to the vessels. (b) Intratumoral vessels are chaotic
and often lack pericytes and a proper basement membrane. Reduced blood ﬂow renders the tumor center hypoxic, and tumor cells can invade the
unstable and leaky vessels. VDA treatment results in disruption of the cytoskeleton and reduced cell−cell junctions, further increasing vascular
leakage. This triggers a cascade of events, resulting in a reduction of blood ﬂow, vessel occlusion, and necrosis in the tumor center. In the periphery,
there is a rim of surviving tumor cells that receive nutritional support from nearby blood vessels, which are less responsive to VDAs.
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The prototype compound among VDAs acting at the
colchicine site in tubulin is combretastatin A-4 (4, CA-4)
(Figure 2a), a natural product isolated from Combretum
caﬀum.21 Binding of CA-4 to the colchicine site was established
early through a competitive-binding assay.22 Additional studies
demonstrated rapid binding of CA-4 to tubulin in contrast to
the relatively slow and temperature-dependent binding of
colchicine. Moreover, dissociation of CA-4 from tubulin in the
presence of high concentrations of radiolabeled colchicine was
quite rapid, indicating a diﬀerent kinetic behavior in tubulin
binding between CA-4 and colchicine.23 CA-4 was the ﬁrst
compound reported to show vascular disrupting properties at a
tolerated dose.24 Although identiﬁed more than two decades
ago, the mechanism of action of CA-4 is still not fully
elucidated. It is known that the binding of CA-4 to tubulin at
the colchicine site inhibits tubulin polymerization, leading to
the activation of RhoA, a protein that is crucial for coordinating
the interactions of F-actin and microtubules in the
cytoskeleton,3 as will later be discussed in section 5.1.1.
In addition, CA-4, as a colchicine site binder, has antimitotic
activity in rapidly proliferating cells by interfering with mitotic
spindle formation and chromosome alignment (see section
5.2.1). Compared to microtubule targeting agents acting at
other tubulin sites (i.e., taxol and vinca alkaloids) for which
drug resistance is an important issue due to P-glycoprotein (P-
gp) or βIII-tubulin overexpression, compounds binding at the
colchicine site retain activity against cell lines that overexpress
these factors.25
The potential therapeutic value of vascular disrupting agents
binding at the colchicine site has led to a plethora of original
and review articles on this subject in recent years. We have
made an eﬀort to refer to these review articles throughout this
Figure 2. (a) Classiﬁcation of VDAs. (b) Incorporation of αβ-tubulin dimers into protoﬁlaments, sheet assembly, and microtubule formation.
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.6b00463
J. Med. Chem. 2016, 59, 8685−8711
8687
Perspective, while it has not been our intention to cover
exhaustively the information that can be found in such articles.
Our review is centered on combretastatin A-4 and how
medicinal chemistry approaches have tried to improve the
limitations of this archetypical VDA (particularly instability and
poor solubility). We have also included compounds whose
structure diﬀers from CA-4 but that have provided signiﬁcant
VDA properties, most of them reaching clinical trials. Because
solubility and delivery have been a signiﬁcant limitation for CA-
4, a brief reference to prodrugs and other approaches meant to
improve the delivery of CA-4 has also been included. Lately, an
increasing number of structures of VDA−tubulin complexes
have been solved. A section will be devoted to this structural
information because it may inspire a new generation of VDAs.
It is also very relevant for the future of this family of therapeutic
agents to dissect the biological actions of CA-4 because this
may pave the way for new interventions. Results obtained from
preclinical and clinical studies have been recently reviewed by
other authors, and the reader is referred to them.15,26−28
As we will discuss later, the biological actions of CA-4 have
been investigated in endothelial and tumor cells including
eﬀects on the cell cycle and on cell morphology as well as
binding to tubulin. Various assays have been established to
investigate these CA-4-mediated eﬀects and to demonstrate the
combretastatin-like behavior of most of the compounds
included in this Perspective. We will brieﬂy mention these
assays here. For more detailed information, we refer to the
review of Barbier et al.29 on the molecular mechanisms of
antitubulin plant-derived drugs.
In general, VDAs and, in particular, CA-4-like compounds,
are submitted to a proliferation assay using tumor (and
endothelial) cell lines. CA-4 and analogues are antimitotic,
blocking cell cycle progression during mitosis, which can be
evidenced by ﬂow cytometry as an increase of cells in G2/M
phase. Additionally, mitotically arrested cells may undergo
apoptosis, noticed by an increase in the subG1 population (see
section 5.2 for pathways involved). To visualize the tubulin-
binding eﬀects of the compounds, mitotic spindle organization
is investigated by immunoﬂuorescence staining of the cells with
an antibody against tubulin. A direct interaction of the
compound with tubulin may be shown by measuring tubulin
polymerization or by biophysical assays to determine the
stoichiometry and the association constant (Ka) including
ﬂuorescence spectroscopy using established ligands or radio-
ligand displacement using [3H]colchicine. It is interesting to
mention that the particularities of tubulin and its associated
proteins (microtubule-associated proteins, MAPs) limit the
employment of some standard techniques such as surface
plasmon resonance (SPR) or ITC to determine kinetics or
binding aﬃnity for a small ligand. For example, the tendency of
tubulin to self-aggregate makes a biophysical method such as
SPR not ideal for these determinations. On the other hand,
ITC has mostly been used to characterize the binding of tubulin
to MAPs such as stathmin30 with just a few examples for small
ligands.
An additional and convenient assay to show that the
compound binds speciﬁcally at the colchicine binding site of
tubulin is a recently described competition assay with N,N′-
ethylene-bis(iodoacetamide) (EBI)31 in human breast cancer
MDA-MB-231 cells. EBI is an alkylating agent that speciﬁcally
binds to two cysteine residues present in the colchicine-binding
site of tubulin, Cys239 and Cys354. This β-tubulin adduct can
be detected by Western blot as a second immunoreactive β-
tubulin band that migrates faster than β-tubulin itself. A
compound binding at this site will prevent the formation of the
β-tubulin adduct.32,33
Finally, the capacity to destroy a preexisting vasculature
network formed by endothelial cells on Matrigel, a solubilized
basement membrane that promotes tube formation, provides
evidence for the vascular-disrupting activity of the compound.
This should however be conﬁrmed in vivo by imaging of blood
ﬂow or vascular shutdown in tumor xenografts.
For most VDAs binding at the colchicine site in tubulin,
including CA-4, inhibition of tubulin assembly was found at μM
concentrations while cytoxicity in cell culture assays was
detected at nM or even sub-nM concentrations. As recently
discussed,34 the reason for this apparent inconsistency is not
completely clear, but there are several factors that may
contribute to explain this experimental fact. One factor could
be that the stoichiometry (compound versus tubulin concen-
tration) required in the tubulin (cell-free) assay to achieve an
IC50 value might be completely diﬀerent from the stoichiometry
that exists when inhibiting tubulin in cell culture. It is also
possible that tubulin depolymerization in cells may release
other factors involved in signal transduction so that the
biological eﬀect is ampliﬁed. In addition, there may be factors
directly linked to the limitations and sensitivity of the protein
assay.34
2.4. Classes of Compounds. A huge number of
compounds mimicking combretastatin A-4 have been reported
in recent years, most of which have been covered in excellent
review articles. A Mini-Perspective article has appeared in this
journal in 2006 by Tron et al. covering the medicinal chemistry
of combretastatin A-4.35 A very detailed overview of tubulin
inhibitors binding at the colchicine site was published by Miller
and collaborators, covering compounds reported up to 2010.36
Combretastatin A-4 derivatives have also been reviewed by
Shan et al.,37 Marrelli et al.,38 and very recently by Patil et al.39
A review focusing on cis-restricted isomers has been published
by Rajak et al.40 For those particularly interested in the
synthetic pathways applied to obtain these compounds, relevant
information can be obtained in the review article of Kaur et al.41
Figure 3. Examples of natural products binding tubulin at the colchicine site (5, 6) and a colchicine derivative tested in clinical trials (7).
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Other authors have performed a classiﬁcation of the
compounds based on structural and docking studies, as the
exhaustive review of Alvarez et al.42 An overview of the role
played by computational approaches in the context of the
colchicine-binding domain has also been recently reported by
Massarotti et al.43
In our survey through the diﬀerent families of compounds
that behave as VDAs, we have centered our attention on those
compounds that are active in the nM range in cell culture and/
or for which animal experiments have been conducted as proof
of concept of their VDA capacity. However, no comparison
between data coming from diﬀerent laboratories has been
performed.
2.4.1. Combretastatin and Analogues. Before introducing
combretastatin A-4 and other combretastatins, it should be
mentioned that there are a signiﬁcant number of natural
products whose structure resembles that of colchicine and for
which binding at the colchicine site in tubulin and a
combretastatin-like behavior has been proven. These include
polygamain (5)44 or podophyllotoxin (6)45 as relevant
examples (Figure 3). Among colchicine semisynthetic deriva-
tives, the compound that has reached further development has
been the phosphate prodrug of N-acetylcolchinol 7 (ZD6126).
This compound presented a higher vascular disrupting than
antimitotic activity, but its clinical development has been halted
due to severe cardiotoxicity.28
Combretastatin A-4, described by Pettit et al.46 in 1995, is a
cis-stilbene isolated from the bark of the African willow tree
Combretum caﬀrum. Other combretastatins such as combretsa-
tatin A-1 (8, CA-1), with an extra OH on ring B,21 or
combretastatin A-2 (9, CA-2), with a methylenedioxy bridge at
ring A23 (Figure 4), described and studied by the same group,
showed antivascular properties similar to CA-4. However,
combretastatins are characterized by poor solubility and
chemical instability. In the presence of light, heat, or acid
media, but also after in vivo administration, the cis-stilbene
easily isomerizes to the trans-stilbene (Figure 5) that is
signiﬁcantly less potent at inhibiting tubulin polymerization
and cancer cell growth.47 To improve solubility, prodrugs have
been developed both for CA-4 and CA-1. The phosphate
prodrugs CA-4P22 (10, Zybrestat, Fosbretabulin) and CA-1P48
(11, OXI4503) are currently being evaluated in phase II/III and
phase I/II clinical trials, respectively, whereas ombrabulin (12),
the serine derivative of 3′-amino-deoxycombretastatin A-4,49
was discontinued in 2013 after disappointing results from phase
III clinical trials (Figure 4). It is relevant to mention that CA-1,
and by extension its prodrug, can undergo activation to a
cytotoxic ortho-quinone intermediate that may interact with
protein thiols and nucleic acids and stimulate oxidative stress
through superoxide/hydrogen peroxide production.50 This
could help to explain the superior antitumor eﬀect of CA-1
compared to CA-4 and illustrates how subtle diﬀerences in
structure may account for the activation of diﬀerent pathways
relevant for the mechanism of action. We will refer to these
prodrugs in a later section.
Most eﬀorts addressing the synthesis of structural analogues
of combretastatins have been directed to ﬁx the conformation
of the cis-stilbene connecting the two aromatic rings (Figure 6).
It should be kept in mind that the 3,4,5-trimethoxy substitution
pattern in ring A is required for optimal activity, while
modiﬁcations at ring B are tolerated. Still, the 4-methoxy-3-
hydroxy or 4-methoxy-3-amino patterns are the most abundant
B-rings in those compounds with better activity.
A reasonable and highly explored approximation in order to
stabilize the cis-disposition of rings A and B has been the
incorporation of the stilbene into a cis-restricted bridge, as
shown by the general formula 13 (Figure 6). A successful
strategy has been the employment of (heterocyclic) rings,
particularly through a ﬁve-membered ring, so that not only the
conformation is ﬁxed as cis but also the drug-like properties can
be improved both in terms of solubility and chemical stability.
Such heterocyclic rings include heteroaromatic rings like
pyrazole, imidazole, thiadiazole, triazoles and tetrazoles,
isozazoles, or 1,2,3-thiadiazoles, and a detailed revision of
them can be found in Tron et al.,35 Lu et al.,36 and Rajak et al.40
Figure 4. Relevant combretastatins and their prodrugs.
Figure 5. Cis−trans isomerization of CA-4.
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Relevant examples include the 2-aminothiazoles, originally
reported by Ohsumi51 with compound 14 as a prototype and
further explored by Romagnoli et al.,52 aﬀording compounds
with IC50 values ranging from 0.03 to 0.9 nM (Figure 6).
Particularly, compound 15 (TR644) was found to be superior
to CA-4 in inhibiting tubulin polymerization (0.61 ± 0.07
versus 1.2 ± 0.1 μM for CA-4) while a perfect overlapping with
colchicine was shown by competition experiments.52
Other interesting examples of cis-restricted bridges are the N-
methyl imidazoles, as shown in compounds 16 and 17 (Figure
6). The rational in the design of these compounds was that the
basic nitrogen on the imidazole ring might decrease lip-
ophilicity while allowing the synthesis of water-soluble salts.53
Indeed, compounds 16 and 17 showed cytotoxicity in the nM
range and, more importantly, both compounds were found to
present a good pharmacokinetic proﬁle with high oral
bioavailability and excellent in vivo activity against murine
M5076 reticulum sarcoma tumors in mice.53 It is also
interesting to highlight the presence of an indole as ring B in
compound 17. In fact, this ring has been extensively employed
as a B-ring alternative. It is also present in 18 (T115), reported
by Welsh and co-workers,54 where a 1,2,4-triazole has been
used to restrict the conformation of the bridge linking rings A
and B. Also in this case, inhibition of tubulin polymerization
and disruption of a microtubule network, similar to CA-4, was
reported. In a mouse xenograft model using HT-29 human
colon carcinoma or PC3 prostate cancer cells, a signiﬁcant
inhibition of tumor growth was observed after intraperitoneal
administration.55
Among nonaromatic heterocycles bridging rings A and B, the
2-azetidinones (β-lactams), described by Sun et al.,56 have been
proposed as a viable linking alternative. Indeed, compound 1957
(Figure 6) has shown antiproliferative activity in the sub-nM
range and new compounds in this series still continue to be
explored.58 Compared to previous examples, these compounds
include an additional substituent (an aryl in most cases as in
19) and a trans-relationship between the substituents at
positions 3 and 4.
Very recently, quantum mechanics calculations have been
used to study the instability of combretastatin A-4,59 leading to
bicyclic derivatives at rings A or B as an alternative strategy to
stabilize the cis-conﬁguration. Compound 20 (Figure 6),
belonging to this series, was found to provide IC50 values in
the nM range in cell culture and to be active in HT-29 tumor-
bearing nude mice.
Another highly explored way to link rings A and B has been
through a simple carbonyl linker as exempliﬁed by
benzophenone derivatives. In such compounds, the carbonyl
Figure 6. Cis-restricted bridged compounds mimicking CA-4.
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function signiﬁcantly constrains the relative conformation of
the two aryl rings in a quasi cis orientation. Indeed, phenstatin
(21, Figure 7) can be seen as the closest analogue to CA-4
among benzophenones. Phenstatin and its phosphate prodrug
2260 showed inhibitory values similar to those of CA-4P in
antiproliferative assays, while binding to tubulin was equivalent
to that of CA-4. Other relevant examples of benzophenone
derivatives were provided by Lee and co-workers,61 who
explored the incorporation of diﬀerent ﬁve-membered hetero-
cycles at positions 2, 4, and 5 of ring B of the benzophenone
with the aim to improve chemical stability and, particularly,
solubility and PK values. Compound 23 (Figure 7) was
identiﬁed as one of the most potent compounds in this series.
Its L-valine prodrug 24 (CKD-516) further improved its
aqueous solubility and showed marked antitumor eﬃcacy
against murine (CT26 and 3LL9) and human (HCT116 and
HCT15) xenografts in mice. Encouraging results from phase I
clinical trials following intravenous administration have just
been published.62
Very close in structure to benzophenones are 1,1-diaryl-
ketones, some of which have provided very interesting VDA
activities. As mentioned in previous series, in most cases ring A
is kept almost intact with the 3,4,5-trimethoxy substitution
pattern, where ring B has been replaced by bicyclic aromatic
heterocycles. An early example in this series is 25
(BPROL075),63 an indole derivative with IC50 values against
a variety of human tumor cells in a single-digit nM range and
activity in nude mice against xenografts of human gastric
carcinoma MKN-45, human cervical carcinoma KB, and KB-
derived P-gp170/MDR-overexpressing KB-VIN10 cells at
intravenous doses of 50 mg/kg. Applying a scaﬀold-hoping
approach looking for a backup drug candidate,64 the 7-
azaindole derivative 26 was synthesized, providing a signiﬁcant
improvement in oral bioavailability, metabolic stability, and
aqueous solubility (as the HCl salt) although the antiprolifer-
ative activity was reduced 4-fold compared to 25.
Another relevant example is the benzo[b]furane derivative 27
(BNC105),65 structurally related to the indole and whose
phosphate prodrug 28 (BNC105P) is being evaluated in phase
II clinical trials. Compound 27 was selected by Kremmidiotis et
al.66 using an “in vitro” screening approach comparing the
inhibitory activity of compounds on proliferating versus
quiescent endothelial cells to improve the selectivity of
VDAs. They reported that 27 displayed 80-fold higher potency
against endothelial cells that were actively proliferating or
forming capillary tubes compared with nonproliferating
endothelial cells or endothelium found in stable capillaries, a
selectivity that was not observed with CA-4.66 It is interesting
to highlight that, compared to CA-4, 27 exhibited a longer half-
life, larger AUC0−∝, and a lower level of plasma protein binding,
resulting in a higher free drug exposure.65 The favorable
pharmacokinetics and the wider selectivity compared to CA-4
are two important characteristics of 27. It is also relevant to
mention that the compound is cleared from healthy tissues over
24 h, but due to the vascular shutdown eﬀect, a signiﬁcant
percentage of the drug is trapped in the tumor tissue after 24
h.66
The number of benzo[b]furanes, indoles, benzo[b]-
thiophenes with or without substitutions at position 2
(represented by the general formula 29, Figure 7), or
alternative bicyclic heterocycles such as quinolines,67 that
have shown a CA-4 like behavior is very high. Detailed
Figure 7. 1,1-Diaryl ketone derivatives mimicking CA-4.
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structural and biological information about these compounds is
covered in recent review articles.36,40 Also, the linker
connecting both aryl rings is susceptible to modiﬁcations
including sulﬁde, amine, sulfonamide, or ether linkages (as
represented by the general formula 29). Very recently, selenium
has also been used as a linker.68 In many cases, the ketone
provides the best inhibitory activity, but there are examples
where an NH69 or a sulfur linkage70 also provides potent
colchicine site binders with antiproliferative activity in the nM
range. Very close in structure to 1,1-diarylketones are 1,1-
diarylethenes, also designated as isocombretastatins. As a
representative example, we refer to compound 30, described
by Alvarez et al.,71 which shows antiproliferative activity in the
sub-nM range and where the incorporation of the amide
functionality at position 3 of the indole is meant to improve
solubility.
In these 1,1-diaryl ketone derivatives, ring B can be replaced
by a ﬁve-membered heterocycle that is additionally substituted
by an aryl ring directly attached to the heterocycle or linked
through an NH and represented by the general formula 31
(Figure 8). Examples of this series have been reported by
diﬀerent groups: the so-called PAT-compounds (as 32)72
where pharmacokinetic parameters are improved compared to
previous series, the ARAP derivatives (as 33)73 that have also
the potential to strongly inhibit the Hedgehog signaling
pathway, or the 3-arylamino-5-amino-1,2,4-triazoles (as 34)
that have hampered the growth of syngeneic hepatocellular
carcinoma in Balb/c mice.74
Chalcones represent another important group of colchicine
site binders. They are abundantly present in natural products as
precursors of ﬂavonoids. Their biological activities are very
diverse and include antitumoral properties.75 The antimitotic
activity of chalcones and their capacity to aﬀect tubulin
assembly have been reviewed.76 Chalcones mimicking the
substitution pattern of CA-4, such as 35 (Figure 9), have been
reported by Ducki et al.,77 showing antiproliferative activity in
the nM range. More recently, chalcone 36 has shown in vivo
antitumor activity in A549 tumor xenograft models. Interest-
ingly, compound 36 and similar analogues were found to
exhibit aﬃnity-induced ﬂuorescence during tubulin-binding.78
Also within chalcones, the B-ring can accommodate indol rings,
as exempliﬁed by 37 (IPP51)79 that inhibited tumor growth in
a human bladder xenograft model. Other examples where the
bridge connecting rings A and B contains a pyridine have been
described by Zheng et al.80
2.4.2. Noncombretastatin Colchicine-Site Binders. Up to
here, the compounds described might be considered as
“inspired” by the structure of combretastatins. In this section,
we will refer to compounds that are structurally unrelated to
CA-4 but that have proven to eﬃciently bind tubulin at the
colchicine site and behave as VDAs. We have centered our
attention at those compounds that have reached clinical trials.
The sulfonamide 38 (ABT-751, E7010) (Figure 10) was
reported as a colchicine site binder already in 1997,81 around
the same time the antivascular activity of CA-4 was described.
This compound is active against a broad range of tumor cell
Figure 8. Other modiﬁcations at B-ring on 1,1-diarylketone derivatives.
Figure 9. Chalcone derivatives with a combrestastatin-like behavior.
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lines in vitro and in xenograft models of human gastric,
colorectal, lung, and breast cancer in vivo.82 In addition,
compound 38 is well absorbed after oral administration with an
overall mean Tmax of about 2 h, and results from phase I clinical
trials were reported in 2006.82 However, more recent results on
phase I/II trials were quite discouraging.28 The sulfonamide 38
is also one of the ﬁrst examples, besides DAMA−colchicine,
whose complex with αβ-tubulin has been solved by X-ray
crystallography.83 Other sulfonamides are being explored, like
39.84 This compound can be seen as a conformationally
constrained analogue of 38 and is also a potent tubulin
inhibitor and orally bioavailable.
Plinabulin (40, NPI-2358) is a hydrophilic synthetic
diketopiperazine arising from phenylahistin, a natural product
isolated from Aspergillus sp.85 Plinabulin exhibits potent
antiproliferative activity against a panel of tumor cell lines in
the low nM range and induces tubulin depolymerization.
Because docking studies did not provide clear insights into the
binding mode to tubulin, some chemical probes incorporating
biotin and benzophenone were synthesized and used for
photoaﬃnity studies.86,87 Such studies ﬁnally concluded that
plinabulin interacts in the boundary region between α- and β-
tubulin near or at the colchicine binding site.87 An X-ray crystal
structure of the recently solved complex88 has aﬀorded
additional information on this subject. It is interesting to
highlight that one of the requirements for activity among
plinabulin derivatives is the presence of a rigid and planar
pseudotricyclic structure formed by a hydrogen bond between
the NH of the diketopiperazine and the N of the imidazole.89
Such pseudotricyclic structures have also been proposed as a
requisite for tubulin binding by unrelated compounds such as
1-aroylnaphthalene derivatives90 or cyclohexanediones.32,33
Results from phase I/II clinical trials with plinabulin are
detailed in other reviews.26,28
Figure 10. Colchicine-site binders structurally diﬀerent from CA-4.
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Lexibulin (41, CYT997) is another colchicine site binder
tested in phase I/II clinical trials and whose development has
been discontinued. Its complex with tubulin has just been
solved.88 The discovery of lexibulin started with the
identiﬁcation of the pyrazine analogue 42 while screening the
antiproliferative activity of Cytopia’s library.91 By performing a
focused analogue medicinal chemistry program, a 1000-fold
more potent analogue with activity in the nM range (43) was
identiﬁed. However, its solubility and pharmacokinetics were
unacceptable. By replacing the core heteroaromatic ring
pyrazine to a pyrimidine and by incorporation of a methyl
substituent, as shown in 41, potent antiproliferative activity was
maintained while accompanied by a good pharmacokinetic
proﬁle.91 Additional biological studies conﬁrmed its VDA
activity, with in vivo eﬀects on tumor blood ﬂow.92
Indibulin (44, D-24851) is another example of a compound
class diﬀering from colchicine and CA analogues, identiﬁed in a
cell-based screening assay to discover cytotoxic drugs. Indibulin
has potent cytotoxicity activity in vitro against diﬀerent human
tumor cell lines and in vivo after oral administration to rats
bearing Yoshida AH13 sarcomas.93 Results from phase I clinical
trials indicated a plateau in drug exposure prior to reaching the
maximum tolerated dose, probably related to its poor aqueous
solubility.94 In this sense, there is a very recent article on
indole-3-glyoxylamides that addresses solubility improvement
among this series by reducing the number of aromatic rings and
increasing the count of sp3 atoms, exempliﬁed by compound
45.95 Signiﬁcant growth inhibition in a mouse model of head
and neck cancer has been reported for 45.95
Denibulin (46, MN-029) is the L-alanine prodrug of 47
(MN-022). Rapid metabolization of 46 to the free amine 47
and its N-acetyl derivative has been described. Phase I clinical
trials further showed that denibulin is well tolerated and is able
to decrease tumor vascular parameters following intravenous
infusion.96 It is interesting to highlight that the structure of 47
very much resembles that of nocodazole (48), a well-known
tubulin-depolymerizing agent whose complex with αβ-tubulin
has recently been solved.88
Verubulin (49, MPC-6827, Azixa) represents another
interesting VDA that has reached clinical trials and whose
structure signiﬁcantly diﬀers from that of CA-4 and analogues.
This quinazoline derivative was identiﬁed through a HTS
campaign meant to identify proapoptotic compounds.97 Its
antimitotic properties were shown to be a consequence of the
binding to αβ-tubulin at the colchicine site. Verubulin showed a
high blood−brain barrier penetration98 and has been detected
in the cerebrospinal ﬂuid. However, its high lipophilicity
required a formulation with signiﬁcant side eﬀects, so clinical
trials have been suspended. It has recently been highlighted99
that a similar substitution pattern to that of verubulin is
observed in fused-pyrimidine derivatives reported by Gangjee
et al.100,101 that not only target tubulin but are able to inhibit
receptor tyrosine kinases involved in angiogenesis such as
vascular endothelial growth factor receptor-2 (VEGFR-2) and
platelet-derived growth factor receptor β (PDGFR-β).
2-Methoxyestradiol (50, 2-ME) is an endogenous estrogen
metabolite implicated in diﬀerent processes including inhibition
of tumor vascularization and growth by binding at the
colchicine site.102 However, its rapid metabolization and poor
pharmacokinetics have launched the synthesis and biological
evaluation of novel analogues. As an interesting example, we
include the bis-sulfamate 51 (STX140)103 with excellent oral
bioavailability and whose mechanism of action, besides binding
tubulin, seems to involve other targets including carbonic
anhydrase.104 Other compounds being explored in this series
include steroidomimetic tetrahydroquinolines105 or steroid
derivatives substituted at positions 3 and 17, positions that
are quickly metabolized in methoxyestradiol.106
3. X-RAY STRUCTURES OF TUBULIN AND
TUBULIN−COLCHICINE SITE LIGANDS
3.1. Tubulin Structure. Tubulin is a heterodimer
constituted of two monomers of 50 Kd designated as α and
β subunits, with ca. 40% sequence identity between them. The
ﬁrst structural studies on the αβ-tubulin dimer appeared in
1998, when Nogales et al.107 reported a three-dimensional
Figure 11. Structure of αβ-tubulin in complex with taxol (PDB code 1JFF). Color code for the domain in each monomer: N-terminal in magenta,
intermediate domain in orange, and C-terminal domain in green. Taxol (cyan), GDP, and GTP (green) are shown in sticks.
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model ﬁtted to a 3.7 Å density map obtained by electron
crystallography of zinc-induced tubulin sheets stabilized with
taxol. The atomic model of the tubulin dimer, in a straight
conformation, was further reﬁned to 3.5 Å resolution.108 In this
model, the α and β subunits of tubulin presented the same
overall compact structure, where each monomer could be
divided into three domains (Figure 11). The N-terminal
domain (residues 1−205, magenta in Figure 11) contains the
nucleotide-binding domain and comprises six parallel β-strands
(S1−S6) alternating with six helices (H1−H6). The loops
(T1−T6) joining strands and helices are directly involved in
the binding of the nucleotide. The interaction of the N-terminal
end of the core helix H7 with the second, smaller domain
(residues 206−381, yellow in Figure 11), designated as
intermediate domain, formed by three helices (H8−H11) and
a mixed β-sheet (S7−S10), completes the nucleotide-binding
site. The C-terminal domain (residues 385 to the c-terminus,
green in Figure 11) contains two antiparallel helices (H11−
H12) that cross over the two other domains. This domain
ﬁnishes with the highly acidic tail. Sequence variability in this
C-terminal tail is related to the diﬀerent isotypes of tubulin (six
forms of α-tubulin and 7 forms of β-tubulin).109
Each tubulin monomer binds a guanine nucleotide. The
nonexchangeable GTP is bound into the α subunit in the so-
called N-site buried at the dimer interface, while the
exchangeable GDP is bound into the β subunit (namely E-
site) exposed on the surface of the dimer.
In 2000, using X-ray crystallography, Gigant et al.110 were
able to determine the structure of two αβ-tubulin dimers in
complex with the stathmin-like domain of the neural protein
RB3 (RB3-SLD) at 4 Å. In the overall structure, the RB3
protein adopted a hook-like shape able to accommodate two
tubulin heterodimers so that the complex formed a curved
structure that, as will later be discussed, has important
consequences. Each dimer contained GTP and GDP molecules
located inside α and β subunits, respectively. The strategy to
use stathmin or other “tubulin sequestration” proteins to
stabilize the complex has been critical in solving the structure of
tubulin with diﬀerent ligands.
3.2. Overview of Colchicine−Tubulin Complexes
Based on X-ray Data. Although the structure of the
tubulin−taxol complex was already reported in the late
1990s,107 atomic details of the colchicine-binding site became
apparent only in 2004 when Ravelli et al.18 solved the structure
of αβ-tubulin with the stahmin-like domain of the RB3 protein
in complex with N-deacetyl-N-(2-mercaptoacetyl)colchicine
(DAMA−colchicine, PDB code 1SA0) (Figure 12), indicating
that the N-acetyl group of DAMA−colchicine (52, Figure 13)
was deﬁnitive to unambiguously deﬁne the colchicine
orientation in its asymmetric density. This pioneering work
unraveled that the DAMA−colchicine binding site was located
close to the interface between the α and β subunits of each
tubulin dimer, mostly buried in the intermediate domain of the
β subunit and boxed in by strands S8, S9, helices H7 and H8,
and loop T7 from this subunit (Figure 12). In this binding
mode, the methoxy group of ring A of DAMA−colchicine
establishes a hydrogen-bond interaction with Cysβ241, while
ring C interacts with loop T5 of the N-terminal nucleotide-
binding domain of the α subunit by a H-bond between the
carbonyl group of ring C and the backbone of Valα181. This
model could also explain how colchicine binding might aﬀect
tubulin dynamics. The ternary tubulin−podophyllotoxin:RB3-
SLD complex (6, Figure 13, PDB code 1SA1) was also
described.
Figure 12. Overall structure of the DAMA−colchicine−tubulin complex and detailed insight into the binding mode of DAMA−colchicine. The α
subunit is represented in light pink and the β subunit in light cyan. Colchicine is represented in green in sticks, and relevant amino acids at the
colchicine site are also represented in sticks.
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In 2009, making use of the RB3-SLD complex, the same
research group reported on a set of structures that included an
unliganded tubulin (PDB code 3HKB) and complexes with
three known colchicine site ligands: the sulfonamide 38 (PDB
code 3HKC), the pyrrolidinedione 53 (TN-16, PDB code
3HKD), and the pentaﬂuorophenyl derivative 54 (T13, PDB
code 3HKE)83 (chemical structures in Figure 13). In all cases,
van der Waals contacts between the ligand and the protein
proved to be the most relevant for the interaction, while polar
interactions were very few. The binding of 38 very much
resembles the binding of colchicine, although 38 is more
hidden in β-tubulin than colchicine with no contacts with the
α-subunit. Concerning the binding of 53 (Figure 14), the ligand
appears much more deeply buried in the β subunit, limiting the
overlap to DAMA−colchicine only to the subsite where the
colchicine A-ring is located. Therefore, 53 establishes fewer
contacts with the tubulin intermediate domain, while making
new interactions with the β strands S4, S5, and S6 of the
nucleotide-binding domain of β tubulin. Because of the
accessory pocket explored by 53 inside the β subunit of
tubulin, these new structures allowed expansion of the
deﬁnition of the colchicine-binding site to the more extensive
term designated “colchicine-binding domain”.83 Moreover, it
was possible to identify local changes that contributed to
tubulin curvature in the absence of colchicine site ligands. Local
conformational changes were observed when the structures of
the unliganded curved tubulin (T2RB3) and the colchicine−
tubulin complex (T2RB3−colchicine) were compared.18 While
the overall structure and curvature remained unchanged, a
switch of the T7 loop was observed (Figure 15). This loop lies
in the colchicine site when it is empty but moves toward the
dimer interface upon ligand binding.
In 2010 Barbier et al.111 demonstrated that the buried cavity
described for 53 was also occupied by 55 (G2N, Figure 13,
Figure 13. Chemical structures of colchicine site ligands cocrystallized with αβ-tubulin.
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PDB code 3N2G) and 56 (K2N, Figure 13, PDB code 3N2K),
the chiral R and S isomers, respectively, of the mitotic inhibitor
ethyl-5-amino-2-methyl-1,2-dihydro-3-phenylpirido[3,4-b]-
pyrazine-7-yl-carbamate.
It should be mentioned that all the complexes discussed so
far have a low-to-medium resolution, with values between 3.58
and 4.20 Å. More recently, higher-resolution structures (<2.5
Å) have been obtained by Steinmetz’s group using tubulin
tyrosine ligase (TTL), a well-known enzyme involved in the
post-translational modiﬁcations at the C-terminal tail in
tubulin,109,112 as an additional structural protein. Therefore,
crystals containing two heterodimers of tubulin (T2), the
stathmin-like domain of RB3 (R), and TTL were solved at 2.6−
1.8 Å resolution.113 Moreover, by using soaking techniques,
T2RTTL complexes of either microtubule stabilizing114 or
destabilizing ligands115,116 have been reported. In particular, the
complexes of T2RTTL with 57 (BAL27862, Figure 13, PDB
code 4O2A) and with colchicine (3, PDB code 4O2B) were
solved at 2.5 and 2.3 Å resolution, respectively.115
During the last year, using the protein complex T2RTTL,
other authors have determined the structures of structurally
diverse colchicine site binders. Particularly the complexes with
58 (MI-181, Figure 13, PDB code 4YJ2) and 59 (C2, PDB
code 4YJ3)117 were reported in 2015, while early this year
additional complexes with lexibulin (PDB code 5CA0),
nocodazole (PDB code 5CA1), plinabulin (PDB code 5C8Y),
and tivantinib (60, PDB code 5CB4) have been published.88
Surprisingly, although CA-4 is considered the prototype and
best studied VDA, to date, no X-ray structural data of its
binding mode with tubulin are available.
3.3. Structural Details of the “Colchicine Domain”.
The colchicine-binding site is a deep pocket, mostly buried in
the intermediate domain of the β subunit, located near the
interface between α and β subunits of a tubulin dimer. As
already mentioned, the comparison between the crystal
complexes of DAMA−colchicine and 53 with tubulin led to
the proposal that colchicine site ligands bind to tubulin in a
“colchicine domain” which comprises a main site (where
colchicine itself binds) and additional neighboring pockets.
Massaroti et al.43 nicely analyzed by structural interaction
ﬁngerprints (SIFt)118 this colchicine-binding domain and
proposed a division into three zones, designated as zones 1,
2, and 3, as shown in Figure 16a. Zone 1, considered an
accessory pocket, is facing the α subunit interface, surrounded
by residues Valα181, Serα178, Metβ259, and Asnβ258. Zone 2,
or the main zone (in the center of the domain, Figure 16a), is a
hydrophobic pocket located in the β subunit formed by
residues Lysβ352, Asnβ350, Ileβ378, Valβ318, Alaβ317,
Alaβ316, Leuβ255, Lysβ254, Leuβ252, Alaβ250, Leuβ248,
Leuβ242, and Cysβ241. Finally, zone 3, the second accessory
pocket, is buried deeper in the β subunit and is formed by
residues Thrβ239, Valβ238, Tyrβ202, Gluβ200, Pheβ169,
Asnβ167, Glnβ136, and Ileβ4.
Taking the crystal structure of colchicine complexes as
reference, colchicine-domain ligands (CDLs) can be divided
into two main groups. There are a number of ligands (6, 38, 41,
54, 57, and 60, Figure 13) that bind similarly to colchicine,
occupying zones 1 and 2. A superposition of their binding
Figure 14. (a) Crystal structure of the complex of tubulin with the pyrrolidinedione 53. The α subunit of tubulin is represented in light pink and the
β subunit in light cyan. (b) View of the binding mode of 53 represented in sticks (cyan) after a 180° rotation. For comparison, DAMA−colchicine is
shown in green sticks.
Figure 15. Conformation change of the T7-loop upon colchicine
binding. α-Tubulin in the unbounded state is represented in magenta
and β-tubulin is represented in blue; the α-tubulin in the colchicine
complex is represented in light pink, while β-tubulin is represented in
pale cyan.
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modes can be seen in Figure 16b. The second group collects a
number of ligands (40, 48, 55, 56, and 58, Figure 13) that
mimic the binding of the pyrrolidinedione 53, occupying zones
2 and 3, and whose superpositions are shown in Figure 16c.
When comparing the superposition in Figure 16b,c, it could be
argued that planar compounds tend to locate deeper into the β-
subunit making use of zones 2 and 3, whereas more globular or
butterﬂy like shaped ligands occupy zones 1 and 2, mimicking
the colchicine-binding mode. Moreover, none of the available
crystal complexes shows ligands that occupy the entire
colchicine domain.
It should also be mentioned that the pentaﬂuorophenyl
derivative 54 has been reported to covalently bind to tubulin.83
Moreover, two binding modes have been described in the same
Figure 16. (a) The colchicine-binding domain. The α subunit of tubulin is represented in light pink and the β subunit in light cyan. Residues from
zone 1 (yellow), zone 2 (green), and zone 3 (violet) are shown in sticks. (b) Superposition of the ligands mimicking the colchicine-binding mode: 6
(brown), 38 (light orange), 41 (white), 52 (blue), 54 (light-pink and cyan), 57 (green), 59 (pink), and 60 (yellow). (c) Superposition of ligands
mimicking the pyrrolidinedione-binding mode: 40 (orange), 48 (marine blue), 53 (pink), 55 (light pink), 56 (light yellow), and 58 (cyan). For
chemical structures of the ligands, see Figure 13.
Figure 17. (a) Superposition of the N-terminal domain of β-subunits of the straight (slate blue) and curved (light cyan) conformations of tubulin.
The α-subunit of the straight state is shown in gray, and colchicine is shown in sticks (green). In the straight tubulin (slate blue), the T7-loop
occludes the colchicine site when compared to the curved tubulin (light cyan). (b) Curved-to-straight conformational transition of αβ-tubulin upon
GTP binding required for microtubule growth. Binding of colchicine (represented by a yellow pentagon) into the αβ-tubulin dimer prevents the
conformational transition and suppresses microtubule dynamics.
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crystal, shown in white in Figure 16b and in cyan in Figure 16c.
Finally, the reader is referred to the original publications for a
more detailed description of the binding mode of each of these
ligands.
3.4. Microtubule Destabilization by CDLs: Straight
versus Curved Tubulin. As mentioned before, tubulin dimers
in microtubules adopt a straight conformation107,108 while a
curved conformation is found for tubulin in solution.119,120
Therefore, a “curved-to-straight” structural transition of the αβ-
tubulin dimer is required for microtubule formation and needs
the rearrangement of several secondary structural elements,
especially concerning the intermediate domain.18,83 Moreover,
the comparison of the curved tubulin−colchicine structure with
the straight state of tubulin18 (Figure 17a) shows that this
conformational change in tubulin leads to the movement of the
T7-loop toward the colchicine site, closing the cavity. This
switch in the T7-loop suggests that colchicine cannot bind into
tubulin in preformed microtubules,18,83 although tubulin−CDL
complexes can be incorporated into growing microtubules.121
Thus, the microtubule-destabilizing activity of CDLs should
consist in preventing the curved-to-straight transition in tubulin
by the bound ligand, thus perturbing the microtubule end
(Figure 17b). This behavior diﬀers from other microtubule-
destabilizing agents that do not behave as VDAs, such as vinca
alkaloids, that bind at the interdimer interface and destabilize
microtubule ends by producing a molecular wedge between two
longitudinally aligned tubulin dimers, inducing curved protoﬁla-
ment assemblies incompatible with the straight conformation in
microtubules.122 It is conceivable that these diﬀerences in
destabilizing tubulin might account for the distinctive biological
activities of vinca alkaloids and colchicine-based VDAs.
4. PRODRUGS AND OTHER APPROACHES TO
IMPROVE DRUG DELIVERY
As shown in previous sections, combretastatins and most of
their structural derivatives suﬀer from very low solubility so that
prodrug formulation has been a must in order to progress to
preclinical evaluation. For compounds containing a phenolic
OH, such as CA-4 (4), CA-1 (8), phenstatin (21), or the
benzofurane derivative 27, the most applied strategy has been
the derivatization as phosphate prodrugs, as recently
summarized by Boyle et al.123 Such prodrugs have good
chemical stability and are rapidly converted to the active drug in
vivo due to the action of phosphatases. As an illustrative
example, the half-life of CA-4P (10) is just a few minutes and
the prodrug needs to be administered by infusion. Metabolism
of CA-4 includes Z to E isomerization, O-demethylation, and
glucuronidation, as recently reviewed.25 Certainly, CA-1P (11)
represents a particular case. As mentioned, CA-1 and its
diphosphate prodrug have remarkable cytotoxicity, superior to
that of CA-4. It has been proposed that this increased activity
can be partially ascribed to its rapid metabolization, giving rise
to reactive quinones. Still, it is diﬃcult to quantify the
contribution of these now well-characterized quinones to the
overall antitumor activity of CA-1.124
Although the derivatization as phosphates has clearly
improved the aqueous solubility of CA-4 and CA-1, the
resulting prodrugs are charged at physiological pH and are
cleaved by nonspeciﬁc phosphatases. Thus, phosphate prodrugs
work nicely when administered parentally, but oral admin-
istration is generally unsuccessful.125
If the derivatization point in the parent drug is an amino
group, coupling to amino acids is the reaction of choice, so that
the prodrugs are cleaved by the action of aminopeptidases. The
most relevant example in this series is ombrabulin (12), the
serine derivative of 3′-amino-deoxycombretastatin A-4, a
prodrug that has reached clinical trials. Pharmacokinetics have
conﬁrmed the rapid conversion of ombrabulin to its active
amino metabolite so that the mean half-life of the prodrug is 12
min.126 Interestingly, the terminal half-life of the active
metabolite was 8 h. This supports a greater metabolic stability
of the amine-derived combretastatin analogues and derivatives
in comparison with their OH counterparts. Intravenous
infusion was also the way of administration for ombrabulin in
the reported clinical studies.
Another example is 24, an L-valine prodrug of a 2-
aminothiazole derivative. Derivatization as prodrug made it
feasible to get the solubility required for in vivo studies.61
Results from phase I clinical trials62 indicate that after
intravenous infusion, biotransformation to the amino derivative
was almost complete, with only <1% of unchanged 24 being
excreted in the urine, whereas the half-life of the active amino
metabolite ranged from 4 to 6 h.
An interesting approach in the design of prodrugs is the work
performed by You and co-workers127 using photo-unclick
chemistry to develop light-activatable prodrugs of combretas-
tatin A-4. These prodrugs combine in their structure folic acid
as a tumor targeting unit for folate receptor uptake,
phthalocyanine as a photosensitizer and reporter, and the
aminoacrylate bond as the linker for singlet-oxygen drug
release. In addition, the length of the polyethylene spacer helps
in the uptake of the prodrug by the tumor cells. The results
obtained indicate that after prodrug administration to mice
inoculated with folate-receptor colon 26 tumors and only after
laser irradiation, a signiﬁcant and selective antitumor eﬀect was
observed.127
Another way to improve the poor aqueous solubility and
pharmacokinetic properties of CA-4 has been through
alternative delivery systems such as polymeric micelles,128
liposomes,129 dendrimers,130 or pH-sensitive nanocarriers.131
These systems do not only improve the solubility and
pharmacokinetics but may allow the delivery of CA-4 to a
particular cell population, using targeted drug delivery systems.
One of the most cited and bright examples with this aim is the
work reported by Sengupta et al. on a nanoscale delivery
system, designated “nanocell” that enables the temporal release
of CA-4 and doxorubicin.132 A more recent example directed
toward a particular cell population involves nanocomplexes in
which CA-4 or 2-ME have been encapsulated in poly(D,L-lactic-
co-glycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG). The
targeting moiety cetuximab, an antiepidermal growth factor
receptor (EGFR) chimeric monoclonal antibody, is incorpo-
rated on the surface of the resulting coronas, which enables the
targeted delivery to human hepatocellular carcinoma cells
overexpressing the EGFR.133
Another interesting approach also in the nanomedicine ﬁeld
has been the coadministration of CA-4P with functionalized
nanoparticles by exploiting the enhanced permeability and
retention (EPR) eﬀect. According to Song et al.,134 in this
system, CA-4P eradicates tumor cells in the central region of
the solid tumor while the cis-diaminedichloroplatinum (CDDP)
loaded nanoparticles (CDDP-NPs) mainly act at the tumor
periphery. In vivo experiments using mouse xenograft models
bearing C26 and MDA-MB-435 tumors evidenced that the
coadministration shows a signiﬁcantly higher anticancer eﬃcacy
compared to CDDP-NPs or CA-4P alone.134
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Related to this, it may be relevant to introduce the so-called
“pharmacokinetic approaches” to cancer treatment, a concept
that has also been recently reviewed.135 According to this
approach, it should be considered that intratumoral pharma-
cokinetics within solid tumor microregions are crucial for
eﬃcacy of the treatment regimens: not only the biophysical
properties of the intratumoral microenvironment signiﬁcantly
diﬀer from normal tissues, but treatment with antivascular
agents as CA-4 or 27 may further alter this microenvironment.
This should be taken into account when selecting the
combination protocol, drug doses, treatment sequence, and/
or durations.135
5. BIOLOGICAL ACTIVITIES THAT CONTRIBUTE TO
THE ANTITUMOR ACTIVITY OF COMBRETASTATIN
A-4
As mentioned earlier in this Perspective, key to the antitumor
activity of CA-4 is the inhibition of tubulin polymerization
thereby impairing the formation of functional microtubules,
which are crucial to cell division, morphology, and movement.
In particular, the tubulin-depolymerizing activity of CA-4 leads
to (i) inhibition of endothelial and tumor cell mitosis, followed
by mitotic catastrophe and/or apoptosis, (ii) cytoskeleton
disruption of endothelial cells, resulting in endothelial cell
shape changes, increased blood vessel permeability, and/or
thrombus formation and vascular collapse, and (iii) inhibition
of cell migration, resulting in antimetastatic activity. In the
following sections, the diﬀerent processes and molecular
pathways involved have been summarized under three crucial
aspects: antivascular eﬀects, induction of cell death, and eﬀects
on cell movement and metastasis. Most of these eﬀects have
been described for CA-4 or its prodrug CA-4P but also for
several combretastatin-like compounds.
5.1. Antivascular Eﬀects. 5.1.1. Vascular-Disrupting
Activity. As mentioned before, tubulin-binding VDAs take
advantage of the unstable and immature intratumoral
vasculature to selectively target tumor blood vessels as opposed
to normal vessels. The kinetics of the antivascular eﬀect of CA-
4P have been extensively investigated using various methods,
including dynamic bioluminescence imaging, intravital micros-
copy, magnetic resonance imaging, and histology.24,136−139
Already in 1997, Dark et al.24 showed that CA-4P induces
vascular shutdown at doses less than one-tenth of the maximum
tolerated dose. Further studies demonstrated that tumor blood
ﬂow was reduced within 1 h and that CA-4P caused the loss of
a large proportion of the smallest blood vessels,136 resulting in a
signiﬁcant reduction in mean vessel radius, as shown later using
MRI-based vessel size imaging.140 However, tumor perfusion
and oxygenation status returned to normal after 24 h following
a single injection of CA-4P.141
Lunt et al.142 demonstrated that the vascular-disrupting eﬀect
of CA-4P dominates the tumor response to CA-4P rather than
direct tumor cell cytotoxicity. These authors showed that
SW122 human colorectal carcinoma cells resistant to CA-4P in
vitro (no inhibition of cell proliferation) were equally sensitive
as nonresistant cells to CA-4P in vivo. Moreover, CA-4P
induced tumor necrosis, rapid vessel disruption, and blood ﬂow
shutdown in xenografts derived from both cell lines.142
The molecular and cellular pathways that support the
maintenance and stability of the tumor microvasculature are
not well-deﬁned. However, important roles have been shown
for pericytes, specialized smooth muscle cells that cover and
stabilize microvessels, and for various adhesion molecules and
integrins that provide survival signals to endothelial cells.8 As
already mentioned, the destabilization of the endothelial
cytoskeleton and increase in vascular permeability induced by
combretastatins and analogues are thought to contribute to the
occlusion of the tumor vasculature, which is immature and
abnormal and lacks essential support by pericytes and basement
membrane.8 In theory, increased permeability could cause a
transient increase in interstitial ﬂuid pressure, which in turn
could induce intratumoral blood vessel collapse. However,
there is no experimental evidence to corroborate this
hypothesis.143 Using a ROCK inhibitor, it was shown that
activation of Rho/ROCK is crucial for the antivascular eﬀects of
CA-4P in tumor-bearing mice.144 Importantly, CA-4P was
found to selectively induce regression of unstable tumor
neovessels both in vitro and in mice by inhibiting cellular
signaling through vascular endothelial-cadherin (VE-cadherin),
a crucial cell-speciﬁc junctional molecule.145 Disruption of the
VE-cadherin/β-catenin/Akt signaling pathway also increased
endothelial cell permeability, leading to rapid vascular collapse
and tumor necrosis. On the other hand, stabilization of VE-
cadherin signaling in endothelial cells or enclosure of
endothelial cells with smooth muscle cells conferred resistance
to CA-4P.145 These data demonstrate the ability of tubulin-
disrupting VDAs to discriminate between normal physiological
vessels and unstable intratumoral vessels, a discrimination that
is critical for their clinical applicability.
5.1.2. Antiangiogenic Activity. Angiogenesis is a complex
multistep process that requires, e.g., the proliferation, migration,
and tube formation of endothelial cells. Besides their
destructive eﬀect on the existing vasculature, several VDAs,
including CA-4 and its analogues146 and deoxypodophyllo-
toxin147 (DPT, the 5-deoxyderivative of compound 6), a
natural product isolated from Anthriscus sylvestris, have also
been shown to inhibit the formation of new blood vessels.
Interestingly, sprout formation and migration were reduced at
concentrations that were not cytotoxic to endothelial
cells.148,149 Using the 2-aminothiazole derivative 15,149 it was
shown that inhibition of angiogenesis and increase in vascular
permeability involved the VE-cadherin/β-catenin signaling
pathway. It has also been proposed that connective tissue
growth factor (CTGF/CCN2), an endogenous antiangiogenic
agent, is involved in the antiangiogenic activity of CA-4P.150
Upregulation of CTGF in microvascular endothelial cells by
CA-4P was dependent on ROCK signaling and was increased
by MAPK/Erk inhibitors, providing a possible explanation for
the improved clinical eﬃcacy of combretastatins when
combined with kinase inhibitors.150
5.2. CA-4P Induces Endothelial and Tumor Cell Death.
Several types of cell death may occur following treatment of
cells with tubulin-binding VDAs, including apoptosis, mitotic
catastrophe, necrosis, and autophagy, which are executed by
distinct and sometimes overlapping pathways.151
5.2.1. CA-4P Induces Mitotic Arrest and Mitotic Catas-
trophe in Endothelial and Tumor Cells. Microtubule-binding
agents typically abrogate appropriate spindle formation during
mitosis, leading to cell cycle arrest in G2/M phase. Mitotic
arrest was demonstrated by elevated levels of cyclin B1 protein
and increased cyclin-dependent kinase (cdc2) activity.
Sustained cdc2 activity was responsible for metaphase
arrest.152−154 Interestingly, Kanthou et al.153 showed that
CA4P-induced endothelial cell death was restricted to
proliferating (mitotic) cells. This may be linked to the fact
that failure of cells to proceed through mitosis has been shown
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to result in mitotic catastrophe, a form of cell death induced by
aberrant chromosome segregation during mitosis or DNA
damage. This process is thought to protect normal cells with
irregular mitosis from becoming aneuploid and potentially
oncogenic, as reviewed in Vitale et al.,155 but it is also induced
by several DNA damaging and microtubule-binding com-
pounds. Accordingly, experimental data obtained in a panel of
human B-lymphoid tumors indicate that mitotic catastrophe is
the primary form of cell death induced by CA-4.154,156 Mitotic
catastrophe has also been reported in various other cell lines
treated with combretastatins, such as lung,157,158 bladder,152
cervical,52 and breast cancer cells.159
5.2.2. Combretastatins Induce Endothelial and Tumor Cell
Apoptosis. Increasing data indicate that mitotic catastrophe
may proceed toward other forms of cell death, such as
apoptosis (or necrosis, depending on the pathways involved).
Two diﬀerent apoptotic pathways have been described: the
intrinsic pathway, which results from mitochondrial damage
and subsequent cytochrome c release from the mitochondria,
and the extrinsic pathway, which is activated as a result of
activation of cell death receptors on the cell surface. Both
pathways typically converge on the activation of caspases,
cysteine-dependent proteases responsible for the organized
disassembly of the cell, as recently reviewed.160
Already in 1998, Iyer et al. showed that the cytotoxic eﬀect of
CA-4 was mediated by the induction of apoptosis, as
characterized by increased caspase-3 activation and internu-
cleosomal DNA fragmentation.161 Moreover, treatment of
acute myeloid leukemias (AMLs) with CA-4P led to disruption
of mitochondrial membrane potential and release of
proapoptotic mitochondrial membrane proteins, resulting in
cell death. This was partially ascribed to caspase activation,
although an increase of the intracellular reactive oxygen species
(ROS) also contributed to CA-4P-induced cytotoxicity in
AML.162 Also in H460 lung cancer cells treated with CA-4,
mitochondrial membrane permeabilization followed by cyto-
chrome c release and caspase activation was observed.158 These
data all point to a predominant mitochondrial involvement (i.e.,
intrinsic pathway) in combretastatin-mediated apoptosis.
Further investigation of the molecular mediators involved
revealed an important role for the Bcl-2 family of proteins.
Using knock-down experiments, it was shown that the
apoptosis-promoting protein Bim (BH3-only protein belonging
to Bcl-2 family), which is sequestered on the microtubule array
(type of interface microtubule organization independent of a
centrosome), is essential for CA-4-induced cell death in H460
lung cancer cells. It has been proposed that Bim promotes the
release of proapoptotic Bax from the prosurvival protein Bcl-2,
resulting in increased tumor cell apoptosis.163 A subsequent
study by these authors disclosed an essential role for the tumor-
suppressor protein p53 in the mitochondrial accumulation of
Bim and resulting apoptotic events in nonsmall cell lung
cancer.164 Additionally, NF-κB and c-Jun N-terminal kinase
(JNK) were found to be crucial for the apoptosis-inducing
capacity of the CA-4 analogue Brimanin, an N-Me imidazole
derivative analogue of 16 with a 3-bromo-3,4-dimethoxyphenyl
as ring A in pancreas and breast carcinoma cell lines.165
In contrast, several studies using solid as well as leukemia cell
lines demonstrated CA-4P-induced cell death independent of
caspase activation153 or poly(ADP-ribose) polymerase (PARP)
cleavage,154 suggesting that apoptosis is not involved or only
plays a minor role in cell death induced by CA-4P. Moreover, in
vitro studies using a stilbene derivative (the 3,5-dimethox-
yphenyl derivative at ring A of 3′-amino-deoxycombretastatin
A-4) reported induction of mitotic catastrophe and apoptosis in
HCT-116 human colon cancer cells but not in B16/F10
melanoma cells.151 In summary, despite some reports that show
apoptosis-independent cell death induced by combretastatins,
the majority of studies demonstrate an involvement of the
mitochondrial apoptosis pathway. However, apoptosis induc-
tion by combretastatins seems to be context- and cell-
dependent and the signaling pathways involved remain ill-
deﬁned.
5.3. CA-4P Inhibits Cell Movement and Metastasis.
Tubulin-binding VDAs do not only block cell mitosis but also
aﬀect endothelial and tumor cell morphology and movement
and prevent tumor cell metastasis. Speciﬁcally, CA-4 reduced
the attachment, migration, and invasiveness of gastric cancer
cells by inhibition of the phosphoinositol (PI)3 kinase/AKT
survival pathway.166 CA-4 also inhibited bladder cancer cell
migration in vitro.152 CA-4P has been shown to attenuate
gastric tumor metastasis and AKT activation in vivo, suggesting
that reduced survival signals contribute to the observed
antimetastatic eﬀects.166 In addition, CA-4P inhibited the
circulation of acute myeloid leukemia cells (AMLs) and the
extent of perivascular leukemic inﬁltrates.162 This eﬀect may be
explained by CA-4P-induced downregulation of vascular
endothelial adhesion molecule (VCAM)-1 expression on the
endothelial cell surface, resulting in reduced interaction of
AMLs with blood vessels and subsequent augmented leukemic
cell death.162 Other combretastatin-like compounds also
inhibited cell migration and/or metastasis.149,167,168 In
particular, compound 12 reduced lymph node metastasis of
LY80 Yoshida sarcoma in mice by shutting down the blood
ﬂow even in small metastases. These observations suggest that
combretastatin-mediated vascular shutdown not only aﬀects
large primary tumors but also micrometastases.168
An important role has been attributed to the Rho/ROCK
pathway in the CA-4-induced antimigration eﬀect. Rho-
associated kinases (ROCK) induce the formation of stress
ﬁbers and focal adhesions by phosphorylating the myosin light
chain (MLC), leading to actin binding to myosin II and
increased contractility as reviewed by Ridley.169 High levels of
Rho/ROCK signaling may further lead to “bleb-driven” cell
migration, in addition to the more frequently used “lamellipo-
dium-based” migration.169 In endothelial cells, CA-4P caused
within minutes the phosphorylation of MLC, leading to
actinomyosin contractility, assembly of actin stress ﬁbers, and
formation of focal adhesions. However, some cells also rapidly
acquired a blebbing morphology, which was associated with
increased monolayer permeability and decreased cell viability.
Cytoskeletal alterations as well as blebbling were abolished by
inhibiting the Rho/ROCK pathway or by blocking activation of
stress-activated protein kinase-2/p38.170 In contrast, the
extracellular-regulated kinases 1 and 2 (ERK-1/2) were
shown to protect against blebbing.170 Rho activation was also
involved in cytoskeleton remodeling induced by other VDAs,
including deoxypodophyllotoxin (DPT)147,171 and the CA-4
analogue brimanin.165
In summary, CA-4P-mediated inhibition of cell motility and
invasion contributes to the observed antitumor and, in
particular, to its antimetastatic activity, and may be the
consequence of alterations in microtubule organization and
associated signaling pathways and/or reduced expression of
adhesion molecules that interfere with tumor cell adhesion to
the vasculature.
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.6b00463
J. Med. Chem. 2016, 59, 8685−8711
8701
6. MECHANISMS OF RESISTANCE AGAINST CA-4P
The eﬃcacy of VDAs in tumor therapy depends on both the
immediate vascular shutdown and the subsequent revasculari-
zation and regrowth of the tumor from the remaining viable
rim. To optimize anticancer treatment with VDAs, it is
imperative to get insights into the process of revascularization
and tumor regrowth, as summarized in this section.
6.1. Regrowth from the Remaining Viable Tumor Rim.
Using 12, it was shown that only intratumoral vessels are
disrupted after treatment of sarcoma xenografts, whereas the
vessels at the tumor−host interface remain unaﬀected.172 Thus,
tumor cells at the necrotic border may survive because they
remain fueled by the vessels at the tumor-host interface. Yao et
al.173 further demonstrated that CA-4P-induced hypoxia in
W256 tumor-bearing rats resulted in increased vascular mimicry
(VM), a recently discovered form of angiogenesis, in which
tumor cells form functional vascular channels without
endothelial cell participation.173
6.2. Induction of a More Aggressive and Hypoxic
Environment. A general consequence of VDA treatment is
blood vessel collapse, resulting in reduced blood ﬂow and
consequently hypoxia in the central tumor area. The major
regulator of neovascularization in tumor tissue is hypoxia
inducible factor (HIF)-1α, which is upregulated under hypoxia.
This transcription factor induces the expression of various
proangiogenic molecules, including cytokines such as vascular
endothelial growth factor (VEGF) and stromal cell-derived
factor (SDF)-1/CXCL12, proteolytic enzymes (e.g., matrix
metalloproteinases (MMPs), and inducible nitric oxide
synthase (iNOS). CA-4P was shown to induce widespread
hypoxia in both peripheral and central parts of the tumor within
1 h after treatment.174 However, 24 h post treatment, when
most of the tumor had turned necrotic, pathophysiological
conditions in the surviving viable rim were returning to normal
and hypoxia was restricted to regions bordering the necrotic
tumor center.174 In vitro, CA-4P increased HIF-1α accumu-
lation and VEGF expression under aerobic conditions. The
compound also activated NF-κB via the small guanosine
triphosphatase RhoA.175
As mentioned above, hypoxia was also responsible for
vascular mimicry induced by CA-4P in tumors through the
HIF-1α-induced EphrinA2/PI3K/MMP signaling pathway,
resulting in the regrowth of the damaged tumor.173 Thus,
although originally proposed as a tumor-killing mechanism,
deprivation of tumor blood ﬂow by antiangiogenic agents and
VDAs may paradoxically select for hypoxia-resistant tumor cells
that may present increased angiogenic and metastatic potential.
6.3. Recruitment of Endothelial Progenitor Cells.
Circulating endothelial progenitor cells (EPC) are a subtype
of stem cells with high proliferative potential that are capable of
diﬀerentiating into mature endothelial cells. Emerging evidence
suggests that these bone marrow-derived cells contribute to
vascularization and tumor progression.176,177 The recruitment
of endothelial progenitors from the bone marrow to the
peripheral blood and the tumor site is thought to be induced by
vascular damage and hypoxia and is regulated predominantly by
VEGF/VEGF receptor and SDF-1/CXCL12/CXCR4 path-
ways.178,179 These factors are upregulated under hypoxia and
activate their respective receptors, which are expressed on the
surface of EPCs. Thus, acute systemic mobilization and homing
of EPCs to the viable tumor rim could promote tumor
regrowth following treatment with a VDA.
The CA-1 prodrug 11 was found to cause a rapid increase in
circulating plasma VEGF, SDF-1, and granulocyte colony
stimulating factor (G-CSF) levels in mice.180 Interestingly, G-
CSF knockout mice failed to mobilize EPCs or to increase
SDF-1 plasma levels, while treatment of tumors in these mice
with 11 led to more necrosis compared with tumors treated in
wild-type mice, suggesting that G-CSF may be a key player in
VDA-induced EPC recruitment and tumor regrowth.180
Moreover, inhibition of EPC mobilization by antiangiogenic
compounds resulted in a reduction in tumor rim size and
enhanced VDA antitumor activity, thus providing a mechanistic
rationale for the enhanced eﬃcacy of VDAs when combined
with antiangiogenic drugs.181
6.4. Recruitment of Neutrophils and Tumor-Associ-
ated Macrophages. The importance of the tumor micro-
environment in tumor progression has been well established
during past years. Besides the tumor vasculature, immune cells
play an important role in tumor pathology. In particular,
neutrophils produce various cytokines and enzymes with pro-
angiogenic activity. In addition, pro-angiogenic TIE2-expressing
macrophages (TEMs) have been shown to stimulate cell
migration and invasion, angiogenesis, and tumor growth.182
Thus, both cell types may increase tumor malignancy.
CA-4P was shown to induce inﬁltration of TEMs in murine
mammary tumors. Inhibition of TEM recruitment by
abrogating the CXCL12/CXCR4 pathway or by genetically
depleting TEMs in tumor-bearing mice increased the eﬃcacy of
CA-4P treatment, suggesting that TEMs contribute to tumor
resistance to VDAs.183
CA4P-induced shutdown of tumor blood ﬂow also resulted
in a signiﬁcant increase in neutrophil inﬁltration into the
tumors.184 Neutrophil activity protected the tumor vasculature
against CA4P-induced injury by the production of nitric oxide,
a molecule with vasodilation and blood ﬂow increasing
capacities.184 Recently, Bohn et al.185 added further proof to
the importance of neutrophils in combretastatin resistance by
demonstrating that neutrophil-depleted mice treated with CA-
4P showed increased intratumoral necrosis. These authors also
demonstrated that neutrophil recruitment induced by CA-4P in
endothelial cells is the result of increased expression of
endothelial cell adhesion molecules, which promote neutrophil
attachment to the tumor vasculature.185 Together, these data
strongly suggest a role for TEMs and neutrophils in reducing
the CA-4P-mediated antitumor eﬀect. Thus, these immune cells
may represent a potential target to be addressed in order to
improve the clinical eﬃcacy of VDA-based therapies.
6.5. Eﬀects of CA-4P on Autophagy. Autophagy is a
catabolic process that facilitates cell survival in conditions of
stress by generating energy via lysosomal degradation of
cytoplasmic constituents. In the context of cancer, autophagy
may thus act as a tumor promotor by supporting survival of
starving tumor cells, as recently reviewed.160
CA-4P was shown to cause autophagy in adenocarcinoma-
derived, but not in ﬁbrosarcoma-containing, tumor xenografts,
suggesting a tumor-dependent mechanism of action.186
Accordingly, inhibition of autophagy by the vacuolar H(+)-
ATPase inhibitor Baﬁlomycin-A1186 or by pretreatment with
autophagy inhibitors (3-methyladenine, 3-MA) or small
interfering RNAs against autophagic genes187 potentiated CA-
4-mediated cell death. The enhanced anticancer activity of the
combination of CA-4 and 3-MA was further conﬁrmed in the
SGC-7901 xenograft tumor model.187
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Using JNK inhibitors, it was shown that the JNK-Bcl-2
pathway is a critical regulator of CA-4-induced autophagy,
which attenuates CA-4-induced apoptosis.187 Taken together,
and although recent data indicate that components of the
autophagic signaling pathway may promote cell death,160
autophagy seems to play predominantly a tumor-promoting
role in combretastatin-treated tumors. It may be proposed that
inhibition of this process, by combination therapy with
autophagy inhibitors, may force VDA-treated tumor cells to
enter apoptosis.
7. COMBINATION THERAPY
The clinical success of VDAs relies on the elimination of the
viable tumor rim that is resistant to these compounds, which
can be achieved by combination with radio/chemotherapy or
antiangiogenic therapy. However, the intrinsic strength of
VDAs to cause rapid vascular shutdown also poses extra
problems in that a reduction of intratumoral tumor blood ﬂow
and oxygen tension prevents the uptake of other anticancer
agents and reduces the eﬃcacy of radiation therapy.
Consequently, scheduling, sequence, and timing become crucial
when considering combination regimens involving VDAs in
order to maximize the therapeutic eﬃcacy.26,188,189 For an
extensive overview of combination therapies involving VDAs,
we refer to several excellent reviews that have recently
appeared.25,190 Here, we only highlight some speciﬁc concepts
that illustrate the possibilities and pitfalls associated with VDA
combination therapies.
7.1. Combination with Antiangiogenic Agents. The
mechanistic rational for combining VDAs with angiogenesis
inhibitors is 2-fold, i.e., antiangiogenic agents may abrogate (i)
neovascularization from the remaining vessels in the tumor rim
and (ii) mobilization of EPC from the bone marrow, as already
indicated in a previous section.181
Although angiogenesis involves various mediators and
pathways, studies have, until recently, largely focused on the
key angiogenic growth factor VEGF. Consequently, clinical
VDA combinations have been limited to the evaluation of CA-4
prodrugs with bevacizumab, a clinically approved monoclonal
antibody targeting VEGF.25,190 Recent phase I trials in patients
with advanced cancer treated with CA-4P 4 h before
administration of bevacizumab showed reduced and sustained
vascular permeability and perfusion compared with CA-4P
alone.191
Despite these promising results, bevacizumab may not be the
ideal antiangiogenic agent to combine with VDAs. Accumulat-
ing clinical data indicate that this monoclonal antibody aﬀords
only limited antitumor activity and causes rapid tumor
resistance due to the expression of other angiogenic factors
by the tumor.192,193 As such, combination with already
approved receptor tyrosine kinase inhibitors that target several
angiogenic factors might provide a better therapeutic beneﬁt.
7.2. Combination with Chemo/Radiation Therapy.
Because of limited perfusion in the center of the tumor,
chemo- and radiotherapy are less eﬀective in killing cells at the
tumor core. Conversely, these therapies are particularly eﬃcient
in the well-vascularized VDA-resistant tumor rim. Therefore,
the use of combinations of chemo/radiotherapy with VDAs
seems a very promising strategy that has progressed to phase II
clinical trials. Most of these studies are still ongoing (https://
clinicaltrials.gov). However, the already disclosed results have
not always been as encouraging as expected. Combination of
CA-4P with carboplatin and paclitaxel gave a higher response
rate in patients with relapsed ovarian cancer.194 However, CA-
4P did not signiﬁcantly improve the survival of patients
suﬀering from anaplastic thyroid cancer treated with
carboplatin/paclitaxel.195 Also, addition of 12 to a taxane
regime did not improve progression-free survival of patients
with metastatic nonsmall cell lung cancer.196
Additional studies should provide more insights into these
variable data. However, appropriate scheduling of chemo/
radiotherapy and VDAs is critical to maximize anticancer
eﬃciency and minimize toxicity of these combinations. Because
chemotherapeutic agents and radiotherapy require an adequate
blood ﬂow, they should theoretically be administered before
VDAs. Indeed, preclinical data demonstrated that irradiation
may prevent tumor recurrence in the tumor rim only when
given before 12.172 Also, cisplatin enhanced tumor killing only
when administered before VDAs.197 Moreover, in a phase I trial
involving patients with various tumors refractory to treatment,
CA-4P increased carboplatin-associated toxicity when adminis-
tered 1 h after the chemotherapeutic agent. Interestingly, bone
marrow toxicity could be avoided when both compounds were
administered on consecutive days.198 Also, the combination of
paclitaxel and VDAs should be carefully monitored. Martinelli
et al.189 reported that treatment of mice bearing breast cancer
with paclitaxel followed by the VDA 7, a prodrug of N-
acetylcolchinol, did not result in a beneﬁcial outcome, probably
because of a protective eﬀect of paclitaxel against the vascular
damage induced by 7. By contrast, improved antitumor eﬃcacy
was observed when 7 was administered before paclitaxel. Thus,
scheduling may be critical in the design of these combination
approaches.
8. CONCLUSIONS AND PERSPECTIVES
Tubulin-depolymerizing agents acting at the colchicine site
have been vastly re-explored in the last 20 years, mostly due to
their vascular disrupting properties in the tumor environment.
From a chemical point of view, compounds binding at the
colchicine site are low molecular weight compounds whose
synthesis, in most cases, can be accomplished by standard
synthetic methods, which has allowed the testing of large
families of compounds and the establishment of well-deﬁned
SAR. Using the structure of CA-4 as inspiration, there are now
compounds for which chemical instability is not an issue but
solubility is still a limitation that is mostly overcome by the
derivatization as prodrugs. As mentioned throughout this
Perspective, several prodrugs of combretastatin derivatives are
being evaluated in clinical trials. There are other compounds,
whose structure is not inspired by CA-4, for which oral
bioavailability has been accomplished, and several of them are
being evaluated in the clinic as well. None of them have yet
been approved.
In the last four years, making use of stathmin or other MAPs,
the structure of αβ-tubulin complexed with a wide variety of
ligands has been solved, shedding light into the detailed atomic
features of their binding in the so-called colchicine-binding
domain. The higher resolution of these complexes compared to
the early examples in 2004 of DAMA−colchicine or
podophyllotoxin tubulin-cocrystals have also revealed unknown
features of the tubulin structure. Indeed, the insights obtained
with these very recent complexes may lead to a reevaluation of
the binding mode previously proposed for some ligands based
on docking studies. As an example, the binding mode predicted
for plinabulin by molecular modeling86 does not correlate with
the interactions observed when the complex of plinabulin with
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αβ-tubulin was very recently solved.88 The detailed information
now available about the colchicine domain and the binding
mode of the diﬀerent ligands will facilitate a more accurate
application of the molecular modeling tools to design new
colchicine-domain ligands. Moreover, recent progress on the
diﬀerent conformations of the αβ-tubulin dimer and the
activities of key proteins that regulate microtubule dynam-
ics122,199 may oﬀer new possibilities for therapeutic inter-
vention.
From a biological point of view, and using CA-4 as a
prototype, it is becoming clear that microtubule depolymeriza-
tion in endothelial cells leads to distinct responses aﬀecting
chromosome organization, cell morphology and permeability,
and cell death. Each of these processes involves several
biological pathways that may be targeted by CA-4. Interestingly,
even a very close analogue of CA-4, CA-1, exerts a more toxic
eﬀect than CA-4 due to the formation of a reactive quinone
intermediate. This illustrates the diﬃculties in predicting the
contribution of these diﬀerent pathways to the antivascular and
antitumor activity of CA-4 analogues.
As has also been shown, P-glycoprotein or βIII tubulin
overexpression is not relevant for resistance among these
compounds. However, rapid tumor recurrence after mono-
therapy with these compounds occurs through the intrinsic
resistance of more stabilized vessels at the tumor border. To
surmount these limitations, VDAs are typically administered in
combination with therapies that speciﬁcally target this viable
tumor rim, such as radio- and chemotherapy. Relevant to this
point, it should be mentioned that recent progress in
understanding the biological actions of VDAs has led to
potentially new combination therapies. So far, preclinical
studies already demonstrated improved antitumor activity
when combretastatins were combined with inhibitors of nitric
oxide synthase,200 autophagy,187 or the recently discovered
mediator of vascular disruption RhoJ,201 an endothelial-
enriched Rho GTPase. In vitro studies further indicated that
inhibitors of various intracellular kinases, such as p38 MAPK202
and JNK,187 may increase CA-4 anticancer eﬃcacy. Also,
neutrophils and TEMs may represent a potential target for
improving the clinical eﬃcacy of VDA-based therapies.183,185
Clinically, combinations assayed so far have been limited to
CA-4 prodrugs as VDA, but other VDAs, such as the more
active compound CA-1P, or VDAs with a structure that is not
related to combretastatins, should be included as well.
Finally, new delivery systems such as nanoparticles or
nanocarriers are being explored for selective delivery of CA-4
and its prodrug CA-4P and also for combination therapy.
Moreover, VDAs might be used to prime the host environment
to become receptive to a second (therapeutic or diagnostic)
agent in the so-called environment-primed nanosystems.203 For
example, ombrabulin selectively increases the expression of p32
(a stress-related protein) on the surface of tumor cells, and this
has been used to recruit nanoparticles decorated with p32-
targeting peptides in the tumor environment.204 This ﬁeld will
certainly oﬀer interesting perspectives for the future.
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with a CSIC contract from the I3P programme, and since 2009 as
Tenured Scientist. Her research interests are in the areas of computer-
aided drug design, homology modeling, docking, molecular dynamic
simulations of biomolecular systems, and virtual screening, and she is
currently focused on the development of new antivascular agents.
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2-ME, 2-methoxyestradiol; 3-MA, 3-methyladenine; AML,
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phosphate prodrug of CA-4; CDDP-NPs, cis-diaminedichlor-
oplatinum loaded nanoparticles; CDL, colchicine-domain
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EPC, endothelial progenitor cells; ERK-1/2, extracellular-
regulated kinases 1 and 2; FAA, 8-ﬂavon acetic acid; G-CSF,
granulocyte colony stimulating factor; (HIF)-1α, hypoxia
inducible factor 1α; HTS, high-throughput screening; iNOS,
inducible nitric oxide synthase; JNK, c-Jun N-terminal kinase;
MAP, microtubule associated protein; MLC, myosin light
chain; MMP, matrix metalloproteinase; MRI, magnetic
resonance imaging; NF-κB, nuclear factor kB; NSCLC,
nonsmall cell lung cancer; PARP, poly(ADP-ribose) polymer-
ase; PDGFR-β, platelet-derived growth factor receptor β; RB3-
SLD, stathmin-like domain of the neural protein RB3; ROCK,
Rho-associated kinase; ROS, reactive oxygen species; SDF-1,
stromal cell-derived factor; SIFt, structural interaction ﬁnger-
prints; T2RB3, two tubulin heterodimers−RB3 complex; TEM,
TIE2-expressing macrophages; TNF-α, tumor necrosis factor-
α; TTL, tubulin tyrosine ligase; (VCAM)-1, vascular
endothelial adhesion molecule; VDA, vascular disrupting
agent; VE-cadherin, vascular endothelial-cadherin; VEGFR-2,
vascular endothelial growth factor receptor-2; VM, vascular
mimicry
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Díaz, J. F.; Camarasa, M. J.; Liekens, S.; Priego, E. M. Novel
colchicine-site binders with a cyclohexanedione scaffold identified
through a ligand-based virtual screening approach. J. Med. Chem. 2014,
57, 3924−3938.
(33) Canela, M. D.; Bueno, O.; Noppen, S.; Saéz Calvo, G.; Estev́ez
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(164) Meńdez-Callejas, G. M.; Leone, S.; Tanzarella, C.; Antoccia, A.
Combretastatin A-4 induces p53 mitochondrial-relocalisation inde-
pendent-apoptosis in non-small lung cancer cells. Cell Biol. Int. 2014,
38, 296−308.
(165) Mahal, K.; Ahmad, A.; Sethi, S.; Resch, M.; Ficner, R.; Sarkar,
F. H.; Schobert, R.; Biersack, B. Role of JNK and NF-κB in mediating
the effect of combretastatin A-4 and brimamin on endothelial and
carcinoma cells. Cell. Oncol. 2015, 38, 463−478.
(166) Lin, H. L.; Chiou, S. H.; Wu, C. W.; Lin, W. B.; Chen, L. H.;
Yang, Y. P.; Tsai, M. L.; Uen, Y. H.; Liou, J. P.; Chi, C. W.
Combretastatin A4-induced differential cytotoxicity and reduced
metastatic ability by inhibition of AKT function in human gastric
cancer cells. J. Pharmacol. Exp. Ther. 2007, 323, 365−373.
(167) Pollock, J. K.; Verma, N. K.; O’Boyle, N. M.; Carr, M.;
Meegan, M. J.; Zisterer, D. M. Combretastatin (CA)-4 and its novel
analogue CA-432 impair T-cell migration through the Rho/ROCK
signalling pathway. Biochem. Pharmacol. 2014, 92, 544−557.
(168) Hori, K.; Saito, S.; Kubota, K. A novel combretastatin A-4
derivative, AC7700, strongly stanches tumour blood flow and inhibits
growth of tumours developing in various tissues and organs. Br. J.
Cancer 2002, 86, 1604−1614.
(169) Ridley, A. J. Rho GTPase signalling in cell migration. Curr.
Opin. Cell Biol. 2015, 36, 103−112.
(170) Kanthou, C.; Tozer, G. M. The tumor vascular targeting agent
combretastatin A-4-phosphate induces reorganization of the actin
cytoskeleton and early membrane blebbing in human endothelial cells.
Blood 2002, 99, 2060−2069.
(171) Wang, Y.; Wang, B.; Guerram, M.; Sun, L.; Shi, W.; Tian, C.;
Zhu, X.; Jiang, Z.; Zhang, L. Deoxypodophyllotoxin suppresses tumor
vasculature in HUVECs by promoting cytoskeleton remodeling
through LKB1-AMPK dependent Rho A activation. Oncotarget 2015,
6, 29497−29512.
(172) Hori, K.; Akita, H.; Nonaka, H.; Sumiyoshi, A.; Taki, Y.
Prevention of cancer recurrence in tumor margins by stopping
microcirculation in the tumor and tumor-host interface. Cancer Sci.
2014, 105, 1196−1204.
(173) Yao, N.; Ren, K.; Jiang, C.; Gao, M.; Huang, D.; Lu, X.; Lou,
B.; Peng, F.; Yang, A.; Wang, X.; Ni, Y.; Zhang, J. Combretastatin A4
phosphate treatment induces vasculogenic mimicry formation of W256
breast carcinoma tumor in vitro and in vivo. Tumor Biol. 2015, 36,
8499−8510.
(174) El-Emir, E.; Boxer, G. M.; Petrie, I. A.; Boden, R. W.; Dearling,
J. L. J.; Begent, R. H. J.; Pedley, R. B. Tumour parameters affected by
combretastatin A-4 phosphate therapy in a human colorectal xenograft
model in nude mice. Eur. J. Cancer 2005, 41, 799−806.
(175) Dachs, G. U.; Steele, A. J.; Coralli, C.; Kanthou, C.; Brooks, A.
C.; Gunningham, S. P.; Currie, M. J.; Watson, A. I.; Robinson, B. A.;
Tozer, G. M. Anti-vascular agent Combretastatin A-4-P modulates
hypoxia inducible factor-1 and gene expression. BMC Cancer 2006, 6,
280.
(176) Peichev, M.; Naiyer, A. J.; Pereira, D.; Zhu, Z.; Lane, W. J.;
Williams, M.; Oz, M. C.; Hicklin, D. J.; Witte, L.; Moore, M. A. S.;
Rafii, S. Expression of VEGFR-2 and AC133 by circulating human
CD34+ cells identifies a population of functional endothelial
precursors. Blood 2000, 95, 952−958.
(177) Nolan, D. J.; Ciarrocchi, A.; Mellick, A. S.; Jaggi, J. S.; Bambino,
K.; Gupta, S.; Heikamp, E.; McDevitt, M. R.; Scheinberg, D. A.;
Benezra, R.; Mittal, V. Bone marrow-derived endothelial progenitor
cells are a major determinant of nascent tumor neovascularization.
Genes Dev. 2007, 21, 1546−1558.
(178) Ceradini, D. J.; Kulkarni, A. R.; Callaghan, M. J.; Tepper, O.
M.; Bastidas, N.; Kleinman, M. E.; Capla, J. M.; Galiano, R. D.; Levine,
J. P.; Gurtner, G. C. Progenitor cell trafficking is regulated by hypoxic
gradients through HIF-1 induction of SDF-1. Nat. Med. 2004, 10,
858−864.
(179) Moschetta, M.; Mishima, Y.; Sahin, I.; Manier, S.; Glavey, S.;
Vacca, A.; Roccaro, A. M.; Ghobrial, I. M. Role of endothelial
progenitor cells in cancer progression. Biochim. Biophys. Acta, Rev.
Cancer 2014, 1846, 26−39.
(180) Shaked, Y.; Tang, T.; Woloszynek, J.; Daenen, L. G.; Man, S.;
Xu, P.; Cai, S. R.; Arbeit, J. M.; Voest, E. E.; Chaplin, D. J.; Smythe, J.;
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.6b00463
J. Med. Chem. 2016, 59, 8685−8711
8710
Harris, A.; Nathan, P.; Judson, I.; Rustin, G.; Bertolini, F.; Link, D. C.;
Kerbel, R. S. Contribution of granulocyte colony-stimulating factor to
the acute mobilization of endothelial precursor cells by vascular
disrupting agents. Cancer Res. 2009, 69, 7524−7528.
(181) Shaked, Y.; Ciarrocchi, A.; Franco, M.; Lee, C. R.; Man, S.;
Cheung, A. M.; Hicklin, D. J.; Chaplin, D.; Foster, F. S.; Benezra, R.;
Kerbel, R. S. Therapy-induced acute recruitment of circulating
endothelial progenitor cells to tumors. Science 2006, 313, 1785−1787.
(182) Lewis, C. E.; De Palma, M.; Naldini, L. Tie2-expressing
monocytes and tumor angiogenesis: Regulation by hypoxia and
angiopoietin-2. Cancer Res. 2007, 67, 8429−8432.
(183) Welford, A. F.; Biziato, D.; Coffelt, S. B.; Nucera, S.; Fisher,
M.; Pucci, F.; Di Serio, C.; Naldini, L.; De Palma, M.; Tozer, G. M.;
Lewis, C. E. TIE2-expressing macrophages limit the therapeutic
efficacy of the vascular-disrupting agent combretastatin A4 phosphate
in mice. J. Clin. Invest. 2011, 121, 1969−1973.
(184) Parkins, C. S.; Holder, A. L.; Hill, S. A.; Chaplin, D. J.; Tozer,
G. M. Determinants of anti-vascular action by combretastatin A-4
phosphate: Role of nitric oxide. Br. J. Cancer 2000, 83, 811−816.
(185) Bohn, A. B.; Wittenborn, T.; Brems-Eskildsen, A. S.; Laurberg,
T.; Bertelsen, L. B.; Nielsen, T.; Stødkilde-Jørgensen, H.; Møller, B. K.;
Horsman, M. R. A combretastatin-mediated decrease in neutrophil
concentration in peripheral blood and the impact on the anti-tumor
activity of this drug in two different murine tumor models. PLoS One
2014, 9, e110091.
(186) Greene, L. M.; O’Boyle, N. M.; Nolan, D. P.; Meegan, M. J.;
Zisterer, D. M. The vascular targeting agent Combretastatin-A4
directly induces autophagy in adenocarcinoma-derived colon cancer
cells. Biochem. Pharmacol. 2012, 84, 612−624.
(187) Li, Y.; Luo, P.; Wang, J.; Dai, J.; Yang, X.; Wu, H.; Yang, B.;
He, Q. Autophagy blockade sensitizes the anticancer activity of CA-4
via JNK-Bcl-2 pathway. Toxicol. Appl. Pharmacol. 2014, 274, 319−327.
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